Fairfax Media network navigation

  • Home
  • Shares
  • Share details

CIRCADIAN TECHNOLOGIES LIMITED (CIR)


Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!


General Information
Company Name: Circadian Technologies Limited
Stock Code: CIR
Website: www.circadian.com.au
GICS Sub-Industry: Pharmaceuticals
Market Cap ($M): 13
Equiv. Shares (M): 49

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.245 $ 0.245 $ 0.245 $ 0.245 $ 0.260 1,600 $ -0.015  -5.769 %

Current Broker Consensus Recommendation more
Recommendation: Buy
Recommendation Date: 11th Sep 2009
12 Month Target Price (average): $0
Brokers Surveyed: 1

Company Overview

Business Description:
Circadian Technologies Limited (CIR) is an Australian biotechnology company developing and commercialising angiogenesis-based therapies for the treatment of cancer, eye disease and other diseases. CIR owns rights to develop intellectual property portfolio known as Vascular Endothelial Growth Factors (VEGF) and substantial additional non-VEGF-related intellectual property.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2012  A -4.8 -10.4 -- 0.0 0.0 0.0 --
2011  A -10.3 -22.2 -- 0.0 0.0 0.0 --
2010  A -9.8 -21.6 -- 0.0 0.0 0.0 --
Source: Morningstar analyst estimates.

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2010 A 2011 F 2012 F 2010 A 2011 F 2012 F 2010 A 2011 F 2012 F
Acrux Limited (ACR) $644 M -0.8713 0.9707 0.7463 87.1622 44.2286 25.3272 0.0207 0.0195 0.0452
Circadian Tech. (CIR) $12 M -- -- -- -- -- -- 0.0000 -- --
Pharmaxis (PXS) $62 M -- -- -- -- -- -- 0.0000 -- --

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
CIR -- -- 0.67 -- 23.6
Market 1.10 12.9 0.91 2.56 2.61
Sector 0.93 20.8 2.40 0.55 7.03

Directors
Name Position Start Date
Ms Dominique Gayle Fisher Chairman 04 August 2005
Robert Klupacs Chief Executive Officer,Managing Director 01 March 2008
Ms Tina R McMeckan Non-Executive Director 19 January 2008
Mr Donald Ian Clarke Non-Executive Director 04 August 2005

Management
Name Position
Susan Madden --
Steven Zammit --
Ian Leitch D Director - Clinical Research
Mike Gerometta Head of CMC Development
Mark Sullivan Head of Development
Richard Chadwick Head of Intellectual Property
Megan Baldwin Head of Pre-clinical Research and Development

Substantial Shareholders
Holding Name
7,724,421 (15.91%) Packer and Co Ltd
3,150,340 (6.49%) Licentia Group
3,122,090 (6.43%) Ludwig Institute for Cancer Research Ltd

Calendar of Events
Date Event
24 February 2014 Report (Interim)
17 February 2014 Report (Interim)
21 October 2013 Report (Annual)
22 August 2013 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.

Advertisement

Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Property through Super

An educational booklet on running your own superannuation fund and investing in property.

More details...

News

Consumer gloom spoils day for the big four

The Age 23/05/2013 | The local sharemarket closed lower for a second consecutive day, dragged down by the banks and a surprisingly poor consumer sentiment report.

Fairfax shareholders keen for news on Domain and paywalls

The Age 23/05/2013 | There is a great deal of anticipation for the investor day of Fairfax Media, owner of The Age and The Sydney Morning Herald.

RAMS offer sees shares on the rise

The Age 23/05/2013 | Non-bank lender Resimac has made a bid to acquire the remnants of mortgage firm RAMS in a joint proposal with former Babcock & Brown banker Trevor Loewensohn.

Myer all out to chase sales

The Age 23/05/2013 | Department store Myer will switch its focus from relentless cost-cutting to driving sales growth and grabbing a greater slice of the discretionary spend by shoppers.

Bureau signals end of boom in commodities

The Age 23/05/2013 | Australia's top commodities agency has detailed a year of woe for the local resources industry and joined the Reserve Bank in declaring the peak of investment in the sector.

Telstra to axe jobs in major shake-up

The Age 23/05/2013 | Significant job losses are expected at Telstra after the telco announced sweeping changes to its operational structure as it shifts away from its legacy business.

More...

Sponsored Links
Feedback Form